Welcome to our dedicated page for Nextcure news (Ticker: NXTC), a resource for investors and traders seeking the latest updates and insights on Nextcure stock.
NextCure, Inc. develops targeted cancer therapies as a clinical-stage biopharmaceutical company, with news centered on antibody-drug conjugate programs and related financial updates. Its principal update themes include SIM0505, a Cadherin-6-directed ADC with a topoisomerase 1 inhibitor payload, and LNCB74, a B7-H4-directed ADC.
Company announcements also cover clinical data presentations, FDA interactions such as Fast Track designation for SIM0505 in platinum-resistant ovarian cancer, collaborations with Simcere Zaiming, business updates, financial results, and participation in healthcare investor conferences.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
NextCure (Nasdaq: NXTC), a clinical-stage biopharmaceutical company, announced its presentation at the 22nd Annual Needham Virtual Healthcare Conference on April 19, 2023, at 10:15 am ET. The event will include a live audio webcast accessible through the company's website, with a replay available for 30 days afterward. NextCure focuses on developing novel immunomedicines for cancer and immune-related diseases using its proprietary FIND-IO™ platform. The company aims to address unmet medical needs for patients unresponsive to existing therapies. This announcement comes amidst discussions about the company's growth strategies and future prospects in the biopharmaceutical market.
NextCure, Inc. (NXTC) has provided a business update and reported its full-year financial results for 2022. The company is focused on three clinical programs, with clinical data updates expected in 2023. Notably, NC525 (LAIR-1 mAb) has dosed its first patient in a Phase 1 trial for acute myeloid leukemia (AML). As of December 31, 2022, NextCure ended the year with approximately $160 million in cash, which is projected to fund operations into mid-2025. However, the company reported a net loss of $74.7 million for 2022, an increase from a $69.4 million loss in 2021, driven by rising research and development costs.
BELTSVILLE, Md., Feb. 7, 2023 (GLOBE NEWSWIRE) -- NextCure (Nasdaq: NXTC), a clinical-stage biopharmaceutical company, announced its presentation at the SVB Securities Global Biopharma Conference on February 15 at 1:40 pm ET. Investors can access a live audio webcast via the company's website, with a replay available for 30 days post-event.
NextCure focuses on developing novel immunomedicines for cancer and immune-related diseases using its proprietary FIND-IO™ platform. The company aims to provide new treatment options for patients who do not respond to existing therapies.
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company, announced participation in several upcoming investor conferences. The events include the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 3:30 pm ET, the JMP Securities Hematology and Oncology Summit (virtual) on December 6, 2022, at 10:00 am ET, and the Bank of America Securities 2022 Biotech SMID Cap Conference (virtual) on December 8, 2022, at 3:20 pm ET. Webcasts will be available on the company's website, with replays archived for 30 days.